The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 07, 2022

Filed:

Jul. 31, 2020
Applicant:

Medtronic Ardian Luxembourg S.a.r.l., Luxembourg, LU;

Inventors:

Garrett Pilcher, Windsor, CA (US);

Robert Melder, Santa Rosa, CA (US);

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 18/14 (2006.01); A61N 7/02 (2006.01); A61N 1/00 (2006.01); A61N 1/36 (2006.01); A61B 5/00 (2006.01); A61N 1/05 (2006.01); A61N 7/00 (2006.01); A61B 18/00 (2006.01); A61B 90/00 (2016.01); A61B 18/02 (2006.01); A61B 18/18 (2006.01); A61B 18/24 (2006.01);
U.S. Cl.
CPC ...
A61B 18/1492 (2013.01); A61B 5/40 (2013.01); A61N 1/00 (2013.01); A61N 1/0551 (2013.01); A61N 1/36002 (2017.08); A61N 7/00 (2013.01); A61N 7/02 (2013.01); A61N 7/022 (2013.01); A61B 5/4035 (2013.01); A61B 18/02 (2013.01); A61B 18/1815 (2013.01); A61B 18/24 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00547 (2013.01); A61B 2018/00559 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/0212 (2013.01); A61B 2018/1861 (2013.01); A61B 2090/374 (2016.02); A61B 2090/376 (2016.02); A61B 2090/378 (2016.02); A61N 2007/0043 (2013.01);
Abstract

Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.


Find Patent Forward Citations

Loading…